Just one in 20 U.S. children and teens gets the amount of sleep, exercise and screen time that doctors recommend for optimal health, a new study suggests.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Eli Lilly and Company and Incyte Corporation announced that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis.
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
Accelerated Evolution Biotechnologies’s claims to have found a cure for cancer are, appropriately, being met with global skepticism.
Roche Holding and partner AC Immune called a halt to two late-stage studies of the companies’ crenezumab drug for early Alzheimer’s, the latest in a string of failures to find a treatment for the progressive brain disease.
Pfizer and Eli Lilly announced that tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthritis pain in a Phase III trial.
Takeda Pharmaceutical’s experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of a late-stage clinical trial.
Boston-based Alexion’s Ultomiris (ravulizumab-cwvz) hit the primary objective in a Phase III study of complement inhibitor-naïve patients with atypical hemolytic uremic syndrome.
Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.
Clinical Trial Finds Formula in Merix Pharmaceutical’s RELEEV 1 Day Cold Sore Highly Active Against Herpes
Merix Pharmaceutical Corp. announced the company’s proprietary botanical extract formula VIRACEA was found to be highly active against HSV-1 and HSV-2 in laboratory testing.